Bisoprolol in therapy of arterial hypertension and ischemic heart disease


Дәйексөз келтіру

Толық мәтін

Аннотация

Beta-blockers (BB) are associated with decreasing of mortality and other cardiovascular endpoints in patients with arterial hypertension (AH), acute and chronic forms of ischemic heart disease (IHD). BB are especially effective in decreasing of fatal ventricular arrhythmias in patients with high risk of sudden cardiac death. Selective beta1-BB without intrinsic sympathomimetic activity bisoprolol is characterized by high bioavailability, long elimination half-life, well-balanced clearance. Clinical studies demonstrated positive effect of bicoprolol on cardiovascular morbidity and mortality in patients with AH and IHD.

Авторлар туралы

A Kirichenko

A Kirichenko

Әдебиет тізімі

  1. Goldstein S. β-blocking drugs and coronary heart disease. Cardiovasc Drugs Ther 1997;71:219-25.
  2. Baker JG. The selectivity of beta-adrenoceptor antagonists at the human beta1, beta2 and beta3 adrenoceptors. Br J Pharmacol 2005;144(3):317-22.
  3. Nuttall SL, Routledge HC, Kendall MJ. A comparison of the beta1-selectivity of three beta-blockers. J Clin Pharmacol 2003;28(3):179-86.
  4. Brixius K, Bundkirchen A, Bolck B, et al. nebivolol, bucindolol, metoprolol and carvedilol are devoid of intrinsic sympathomimetic activity in human myocardium. Br J Pharmacol 2001;133(8):1330-38.
  5. Leopold G, Pabst J, Ungethum W, et al. Basic pharmacokinetics of bisoprolol, a new highly beta 1 selective adrenoreceptor antagonist. J Clin Pharmacol 1986;26:616-21.
  6. Leopold G, Kutz K. Bisoprolol: pharmacokinetic profile. Rev Contemp Pharmacother 1997;8:35-43.
  7. Brode O-E. The pharmacology of bisoprolol. Rev Contemp Pharmacother 1997;8:21-33.
  8. Leopold G. Balanced pharmacokinetics and metabolism of bisoprolol. J Cardiovasc Pharmacol 1986;8(Suppl. 11):S16-S20.
  9. Cheung WK, Begg E, dutta A, et al. Dose proportionality of bisoprolol in man. Pharm Res 1988;5(Suppl.):S159.
  10. Mengden T, Vetter W. The efficacy of bisoprolol in the treatment of hypertension. Rev Contemp Pharmacother 1997;8:55-67.
  11. Кириченко А.А., Флегентова О.Н., Рязанцев А. и др. Бисогамма в постменопаузе у женщин с артериальной гипертензией и кардиалгией // Врач. 2005. № 8. C. 33-37.
  12. Шилов А.М. Бета-блокатор второго поколения в практике лечения артериальной гипертонии // Фарматека. 2008. C. 8-12.
  13. Gosse P, Roudaut R, Herrero G, et al. β-blockers vs angiotensin-converting enzyme inhibitors in hypertension: effects of left ventricular hypertrophy. J Cardiovasc Pharmacol 1990;16(Suppl. 5):145-50.
  14. Frishman W, Bryzinski B, Coulson L, et al. A multifactorial trial design to assess combination therapy in hypertension. Arch Intern Med 1994;154:1461-68.
  15. Van der Ven LL, et al. Age-dependent differences in the efficacy and tolerability of different classes of antihypertensive drugs. Clin Drug Invest 1997;1:16-22.
  16. Haasis R, Bethge H. Exercise blood pressure and heart rate reduction 24 and 3 hours after drug intake in hypertensive patients following 4 weeks of trearment with bisoprolol and metoprolol: a randomized multicentre double-blind study (BISOMET). Eur Heart J 1987;8:103-13.
  17. Amabile G, Serradimigni A. Comparison of bisoprolol with nifedipine for treatment of essential hypertension in the elderly: comparative double-blind trial. Eur Heart J 1987;8(Suppl. M):65-69.
  18. Сидоренко Б.А. β-блокаторы: современныне аспекты применения в кардиологии // Кардиология. 1998. № 2. C. 84-96.
  19. Gibbons RJ, Chatteerjee K, Daley J, et al. ACC/AHA/ACP-ASIM guidelines for the management of patients with chronic stable angina. J Am Coll Cardiol 1999;33:2192-97.
  20. van de Ven LL, Vermeulen A, Tans JG, et al. Which drug to choose for stable anginapectoris: a comparative study between bisoprolol and nitrates. Int J Cardiol 1995;47(3):217-23.
  21. Nerol I, Plaza L, Rodrigp F. Bisoprolol in the treatment of chronic stable angina pectoris. J Cardiovasc Pharmacol 1990;16(Suppl. 5):S208-12.
  22. Gibbons RJ, Chatterjee K, Daley J, et al. ACC/AHA/ACP-ASIM guidelines for the management of patients with chronic stable angina: executive summary and recommendations: a report of the American College of Cardiology/AmericanHeart Association task force on practice Guidelines (Commitee on Management of Patientswith Chronic Stable angina). Circulation 1999;99(21):2829-48.
  23. Weber F, Schneider H, von Arnim T, et al. Heart Rate variability and ischemia in patients with coronary heart disease and stable angina pectories; influence of drug therapy and prognostic value. TIBBS Investigators Group. Total Ischemic Burden Bisoprolol Study. Eur Heart J 1999;20(1):38-50.
  24. de Muinck ED, Lie KI, von Mengden HJ, et al. bisoprolol pilot studies in myocardial infarction. J Cardiovasc Pharmacol 1990;16(Suppl. 5):S196-200.
  25. Antman EM. ST-elevation myocardial infarction: management. In book: "Braunwald's Heart Disease", 8-th edition 2008;51:1233-99.
  26. Cannon CP, Braunwald E. Unstable angina and non-ST-elevation myiocardial infarction. Item Ch. 53:1319-51.
  27. Hjalmarson A. cardiprotection with beta-adrenoreceptor blockers. Does lipophilicity matter? Basic Res Cardiol 2000;95(Supll. 1):I41-45.
  28. MacAlister FA, Teo KK. Antiarrhythmic therapies for the prevention of sudden cardiac death. Drugs 1977;54(2):235-52
  29. Brand DA, Newcomer LN, Freiberger A, et al. Cardiologist's practices compared with practice guidelines: use of beta-blocade after acute myocardial infarction. J Am Coll Cardiol 1995;26:1432-36.
  30. CIBIS-II Investigators and Committees. The Cardiac Insufficiency Bisoprolol Study II (CIBIS-II): a randomized trial. Lancet 1999;353:9-13.
  31. Funk-Bentano C, Lancart R, Lehenzey JY, et al Predictors of medical events in patients enrolled in the Cardiac Insufficiency Bisoprolol Study II (CIBIS-II); a study of the interaction between beta0blocker therapy and occurrence of critical events using analysis of competative risks. Am Heart J 2000;139:262-71.
  32. Hjalmarson A. Prevention of sudden cardiac death with beta-blockers Clin Card 1999;22(Suppl. 5):V11-5.
  33. Ellerbeck EF, Jencks SF, Randorf MJ, et al. Quality of care for Medicare patients with acute myocardial infarction:A for-state pilot study from the cooperative cardiovascular project. JAMA 1995;273:1509-14.
  34. Gottlieb SS, McCarter RJ, Vogel RA. Effect of beta-blocade on mortality in high-risk and low - risk patients after myocardial infarction. N Engl J Med 1998;339:489-97.
  35. Chen J, Redfort MJ, Wang Y, et al. Effectiveness of beta-blocker therapy after acute myocardial infarction in elderly patients with chronic obstructive pulmonary disease or asthma. J Amer Coll Cardiol 2001;7:1950-56.
  36. Терещенко С.Н., Павликова Е.П., Сивков В.И. и др. Применение селективного бета-адреноблокатора бисопрлола у больных острым инфарктом миокарда и сопутствующим хроническим обструктивным бронхитом //Кардиология. 2000. № 9. С. 42-44.
  37. Dorow L, Bethge H, Tonnesmann U. Effects of single oral doses of bisoprolol and atenolo on airway function in nonasthmatic chronic obstructive lung disease and angina pectoris. Eur J Clin Pharmacol 1986;31:143-47.
  38. Chatterjee SS. the cardioselective and hypotensive effects of bisoprolol in hypertensive asthmatics. J Cardiovasc pharmacol 1986;8(Suppl. 1):74-77.
  39. Kjeksus JK, Gilpin E, Cali G, et al. Diabetic patients and beta-blockers after acute myocardial infarction. Eur Heart J 1990;11:43-50.
  40. Forman DE, Gutierrez Bernal JL, Wei JI. Management of acute myocardial infarction in the very elderly. Am J Med 1992;93:315-26.
  41. Chen J, Marciniac TA, Radford MJ, et al. Beta-blocker therapy for secondary prevention of myocardial infarction in elderly diabetic patients. JACC 1999;34:1388-94.
  42. UK Prospective Diabetes Study Group. Tight blood pressure control and risk of macrovascular and microvascular complications in tipe 2 diabetes: UKPDS 38. B Med J 1998;317:703-13.
  43. Jonas M, Reicher-Reiss H, Boyko V, et al. Usefullness of beta-blocker therapy in patients with noninsulin dependent diabetes mellitus and coronary arthery disease. Bezafibrate infarction prevention (BIP) Study Groop. Amer J Cardiol 1996;77:1273-77.
  44. Owada A, Suda S, Hata T, et al. The effect of bisoprolol, a selective beta1-blocker, on glucose metabolism by long-term administration in essential hypertension. Clin Exp Hypertens 2001;23(4):305-16.
  45. Janka HU, Ziegler AG, Disselhoff G, et al. Influence of bisoprolol on blood glucose, glucosuria, and haemoglobin A1 in noninsulin-dependent diabetics. J Cardiovasc Pharmacol 1986;8(Suppl. 11):S96-99.
  46. Heinemann I, Heise T, Ampudia J, et al. Four week administration of an ACE inhibitor and a cardioselective beta-blocker in healthy volunteers: no influence on insulin sensitivity. Europ Heart J 1995;25:595-600.
  47. Schouten O, Poldermans D, Visser L, et al. Fluvastatin and bisoprolol for the reduction of perioperative cardiac mortality and morbidity in high-risk patients undergoing non-cardiac surgery: rationale and design of the DECREASE-IV study. Am Heart J 2004;148(6):1047-52.
  48. Vulpis V, Antonacci A, Prandi P, et al. The effect of bisoprolol and atenolo on glucose metabolism in hypertensive patients with non-insulin dependent diabetes mellitus. Minerva Med 1991;82:189-93.
  49. Fogari R, Zoppi A, Tettamanti F, et al. Beta-blocker effects on plasma lipids in antihypertensive therapy: importance of the duratuon of treatment and lipid status befor treatment. J Cardiovasc Pharmacol 1990;16(Suppl. 5):S76-S80.
  50. Frithz G, Weiner L. Effects of bisoprolol on blood pressure, serum lipids and HDL-cholesterol in essential hypertension. Eur J Clin Pharmacol 1987;32:77-80.
  51. Bulpitt CJ, Connor M, Schulte M, et al. Bisiprolol and nifedipine retard in elderly hypertensive patients : effect on quality of life. J Hum hypertens 2000;14(3):205-12.
  52. Prisant LM, Weir MR, Frishman WH, et al. Self reported sexual dysfunction in men and women treated with bisoprolol, hydrochlorothiazide, enelapril,amlodipine, placebo or bisoprolol/hydrochlorothiazide. J Clin Hypertens (Greenwich) 1999;1(1):22-26.
  53. Bulpitt CJ, Connor M, Schulte M, et al. Bisiprolol and nifedipine retard in elderly hypertensive patients : effect on quality of life. J Hum hypertens 2000;14(3):205-12.
  54. http://www.pharmateca.ru/cgi-bin/statyi.pl?sid=2290&mid=1085056570&magid=172&full=1

Қосымша файлдар

Қосымша файлдар
Әрекет
1. JATS XML
Жүктеу

Осы сайт cookie-файлдарды пайдаланады

Біздің сайтты пайдалануды жалғастыра отырып, сіз сайттың дұрыс жұмыс істеуін қамтамасыз ететін cookie файлдарын өңдеуге келісім бересіз.< / br>< / br>cookie файлдары туралы< / a>